MCF Advisors LLC Boosts Position in Gilead Sciences, Inc. $GILD

MCF Advisors LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 63.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 14,663 shares of the biopharmaceutical company’s stock after buying an additional 5,695 shares during the quarter. MCF Advisors LLC’s holdings in Gilead Sciences were worth $1,800,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of GILD. Norges Bank purchased a new position in Gilead Sciences during the 4th quarter worth approximately $2,617,152,000. Massachusetts Financial Services Co. MA raised its position in Gilead Sciences by 3,763.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after buying an additional 4,113,999 shares during the last quarter. Vanguard Group Inc. raised its position in Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after buying an additional 2,113,692 shares during the last quarter. First Trust Advisors LP raised its position in Gilead Sciences by 154.3% during the 3rd quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after buying an additional 1,874,508 shares during the last quarter. Finally, Invesco Ltd. raised its position in Gilead Sciences by 12.0% during the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after buying an additional 1,618,453 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Citi and Scotiabank both reiterated bullish views on Gilead, with each firm maintaining a Buy rating, which can support investor confidence in the stock. Gilead Sciences (GILD) Receives a Buy from Citi
• Positive Sentiment: Gilead highlighted progress on lenacapavir in South Africa, where the government and Global Fund are accelerating access to the HIV prevention drug, reinforcing the company’s growth story in HIV. Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
• Positive Sentiment: Gilead and Lakefront completed the acquisition of Ouro Medicines, expanding the inflammation/autoimmune pipeline around gamgertamig, a potential first-in-class T cell engager. Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
• Positive Sentiment: Gilead’s inclusion in a list of “best quality growth stocks” may add to the market’s view that the company remains a high-quality large-cap healthcare name. 5 Best Quality Growth Stocks to Buy
• Neutral Sentiment: Industry-wide biopharma M&A remains active, and Gilead was mentioned among the sector’s deal-making leaders, which keeps takeover speculation and pipeline deal optionality in focus. Gilead, Merck, Eli Lilly Lead $106 Billion Biopharma Takeover Wave In 2026
• Neutral Sentiment: Gilead also reported a clinical milestone in its IDEAL PBC trial, which could become a future catalyst if the study continues to progress positively. Gilead’s IDEAL PBC Trial Reaches Key Milestone, Setting Up a New Liver Disease Catalyst

Insider Activity

In other news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the transaction, the chief executive officer directly owned 617,567 shares of the company’s stock, valued at $81,185,357.82. The trade was a 2.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the sale, the chief financial officer directly owned 173,191 shares in the company, valued at $22,907,973.57. This represents a 1.70% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 68,000 shares of company stock valued at $9,047,570 in the last three months. 0.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have issued reports on GILD. TD Cowen raised their price target on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Wolfe Research raised their price target on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Bank of America set a $162.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Finally, Argus raised their price target on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Twenty-six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $156.93.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $129.16 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The firm has a market cap of $160.36 billion, a price-to-earnings ratio of 17.60 and a beta of 0.31. The company has a 50 day moving average price of $134.38 and a 200-day moving average price of $134.31. Gilead Sciences, Inc. has a 1-year low of $104.46 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s payout ratio is 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.